M. Carpelan-holmstrom, S. Nordling, and E. Pukkala, Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry, Gut, vol.54, issue.3, pp.385-392, 2005.
DOI : 10.1136/gut.2004.047191

A. Jemal, R. Siegel, and E. Ward, Cancer Statistics, 2009, CA: A Cancer Journal for Clinicians, vol.59, issue.4, pp.225-274, 2009.
DOI : 10.3322/caac.20006

S. Guerin and C. Hill, Cancer epidemiology in France in 2010, comparison with the USA, Bulletin du cancer, vol.97, pp.47-54, 2010.

E. Simard, E. Ward, and R. Siegel, Cancers with increasing incidence trends in the United States: 1999 through, CA Cancer J Clin, 2008.
DOI : 10.3322/caac.20141

H. Oettle, S. Post, and P. Neuhaus, Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer, JAMA, vol.297, issue.3, pp.267-77, 2007.
DOI : 10.1001/jama.297.3.267

J. Neoptolemos, D. Stocken, and H. Friess, A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer, New England Journal of Medicine, vol.350, issue.12, pp.1200-1210, 2004.
DOI : 10.1056/NEJMoa032295

J. Neoptolemos, D. Stocken, and C. Bassi, Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection, JAMA, vol.304, issue.10, pp.1073-81, 2010.
DOI : 10.1001/jama.2010.1275
URL : http://jama.jamanetwork.com/data/journals/jama/4528/joc05113_1073_1081.pdf

Y. Murakami, K. Uemura, and T. Sudo, Number of Metastatic Lymph Nodes, but Not Lymph Node Ratio, Is an Independent Prognostic Factor after Resection of Pancreatic Carcinoma, Journal of the American College of Surgeons, vol.211, issue.2, pp.196-204, 2010.
DOI : 10.1016/j.jamcollsurg.2010.03.037

M. Tempero, M. Malafa, and M. Hawary, Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology, Journal of the National Comprehensive Cancer Network, vol.15, issue.8, pp.1028-61, 2017.
DOI : 10.6004/jnccn.2017.0131

C. Verbeke and A. Smith, Survival After Pancreaticoduodenectomy Is Not Improved by Extending Resections to Achieve Negative Margins, Annals of Surgery, vol.251, issue.4, pp.776-783, 2010.
DOI : 10.1097/SLA.0b013e3181d57af6

I. Esposito, J. Kleeff, and F. Bergmann, Most Pancreatic Cancer Resections are R1 Resections, Annals of Surgical Oncology, vol.92, issue.6, pp.1651-60, 2008.
DOI : 10.1007/3-540-27449-9_5

J. Delpero, P. Bachellier, and N. Regenet, Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens, HPB, vol.16, issue.1, pp.20-33, 2014.
DOI : 10.1111/hpb.12061

P. Ghaneh, J. Kleeff, and C. Halloran, The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma, Annals of Surgery
DOI : 10.1097/SLA.0000000000002557

J. Neoptolemos, D. Palmer, and P. Ghaneh, Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial, The Lancet, vol.389, issue.10073, pp.1011-1035, 2017.
DOI : 10.1016/S0140-6736(16)32409-6

M. Deoliveira, J. Winter, and M. Schafer, Assessment of Complications After Pancreatic Surgery, Annals of Surgery, vol.244, issue.6, pp.931-938, 2006.
DOI : 10.1097/01.sla.0000246856.03918.9a

D. Gouma, R. Van-geenen, and T. Van-gulik, Rates of Complications and Death After Pancreaticoduodenectomy: Risk Factors and the Impact of Hospital Volume, Annals of Surgery, vol.232, issue.6, pp.786-95, 2000.
DOI : 10.1097/00000658-200012000-00007

L. Page, S. Caputo, S. Kwiatkowski, F. Berard, P. Gouillat et al., S??quelles fonctionnelles et qualit?? de vie apr??s duod??nopancr??atectomie c??phalique, Journal de Chirurgie, vol.145, issue.1, pp.32-38, 2008.
DOI : 10.1016/S0021-7697(08)70299-0

W. Regine, K. Winter, and R. Abrams, Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma, JAMA, vol.299, issue.9, pp.1019-1045, 2008.
DOI : 10.1001/jama.299.9.1019

H. Oettle, P. Neuhaus, and A. Hochhaus, Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer, JAMA, vol.310, issue.14, pp.1473-81, 2013.
DOI : 10.1001/jama.2013.279201

S. Gillen, T. Schuster, M. Z. Buschenfelde, and C. , Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages, PLoS Medicine, vol.23, issue.4, p.1000267, 2010.
DOI : 10.1371/journal.pmed.1000267.s005

C. Tzeng, T. Cao, H. Lee, and J. , Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival, Journal of Gastrointestinal Surgery, vol.250, issue.2, pp.16-24, 2014.
DOI : 10.1097/SLA.0b013e3181afde41

R. Merkow, K. Bilimoria, and J. Tomlinson, Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic Cancer, Annals of Surgery, vol.260, issue.2, pp.372-379, 2014.
DOI : 10.1097/SLA.0000000000000378

J. Valle, D. Palmer, and R. Jackson, Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study, Journal of Clinical Oncology, vol.32, issue.6, pp.504-516, 2014.
DOI : 10.1200/JCO.2013.50.7657

H. Ueno, T. Kosuge, and Y. Matsuyama, A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer, British Journal of Cancer, vol.25, issue.6, pp.908-923, 2009.
DOI : 10.1002/cncr.23174

J. Hoffman, S. Lipsitz, and T. Pisansky, Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study., Journal of Clinical Oncology, vol.16, issue.1, pp.317-340, 1998.
DOI : 10.1200/JCO.1998.16.1.317

F. Motoi, K. Ishida, and F. Fujishima, Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 Trial, Annals of Surgical Oncology, vol.142, issue.12
DOI : 10.1016/j.surg.2007.05.005

, Ann Surg Oncol, vol.20, issue.12, pp.3794-801, 2013.

H. Takahashi, H. Ohigashi, and K. Gotoh, Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer, Annals of Surgery, vol.258, issue.6, pp.1040-50, 2013.
DOI : 10.1097/SLA.0b013e31829b3ce4

D. Palmer, D. Stocken, and H. Hewitt, A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin, Annals of Surgical Oncology, vol.223, issue.11, pp.2088-96, 2007.
DOI : 10.1038/bjc.1996.18

G. Varadhachary, R. Wolff, and C. Crane, Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head, Journal of Clinical Oncology, vol.26, issue.21, pp.3487-95, 2008.
DOI : 10.1200/JCO.2007.15.8642

D. Evans, G. Varadhachary, and C. Crane, Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head, Journal of Clinical Oncology, vol.26, issue.21, pp.3496-502, 2008.
DOI : 10.1200/JCO.2007.15.8634

R. White, H. Hurwitz, and M. Morse, Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas, Annals of Surgical Oncology, vol.18, issue.10:, pp.758-65, 2001.
DOI : 10.1007/s10434-001-0758-1

M. Reni, G. Balzano, and G. Aprile, Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial, Annals of Surgical Oncology, vol.16, issue.7, pp.2256-63, 2012.
DOI : 10.3748/wjg.v16.i39.4883

V. Picozzi, R. Abrams, and P. Decker, Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031, Annals of Oncology, vol.248, issue.2, pp.348-54, 2011.
DOI : 10.1097/SLA.0b013e3181820d35

H. Takahashi, H. Ohigashi, and K. Gotoh, Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer, Annals of Surgery, vol.258, issue.6, pp.1040-50, 2013.
DOI : 10.1097/SLA.0b013e31829b3ce4

A. Mokdad, R. Minter, and H. Zhu, Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis, Journal of Clinical Oncology, vol.35, issue.5, pp.515-537, 2017.
DOI : 10.1200/JCO.2016.68.5081

M. Suker, B. Beumer, and E. Sadot, FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis, The Lancet Oncology, vol.17, issue.6, pp.801-811, 2016.
DOI : 10.1016/S1470-2045(16)00172-8

S. Rombouts, M. Walma, and J. Vogel, Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer, Annals of Surgical Oncology, vol.155, issue.6, pp.4352-60, 2016.
DOI : 10.1016/j.surg.2014.02.001

D. Pietrasz, L. Marthey, and M. Wagner, Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort, Annals of Surgical Oncology, vol.11, issue.9, pp.1196-205, 2015.
DOI : 10.1016/S1470-2045(10)70172-8

C. Ferrone, G. Marchegiani, and T. Hong, Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer, Annals of Surgery, vol.261, issue.1, pp.12-19, 2015.
DOI : 10.1097/SLA.0000000000000867

M. Ghosn, A. Saroufim, and J. Kattan, Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer, Medical Oncology, vol.12, issue.2, pp.2831-2838, 2012.
DOI : 10.1056/NEJMoa1011923

H. Oettle, H. Riess, and J. Stieler, Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial, Journal of Clinical Oncology, vol.32, issue.23, pp.2423-2432, 2014.
DOI : 10.1200/JCO.2013.53.6995

F. Bonnetain, B. Bonsing, and T. Conroy, Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials), European Journal of Cancer, vol.50, issue.17, pp.2983-93, 2014.
DOI : 10.1016/j.ejca.2014.07.011
URL : https://hal.archives-ouvertes.fr/hal-01802621

C. Bellera, M. Pulido, and S. Gourgou, Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints??? definitions in cancer clinical trials, European Journal of Cancer, vol.49, issue.4, pp.769-81, 2013.
DOI : 10.1016/j.ejca.2012.09.035

D. Fitzsimmons, C. Johnson, and S. George, Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer, European Journal of Cancer, vol.35, issue.6, pp.939-980, 1999.
DOI : 10.1016/S0959-8049(99)00047-7

D. Dindo, N. Demartines, and P. Clavien, Classification of Surgical Complications, Annals of Surgery, vol.240, issue.2, pp.205-218, 2004.
DOI : 10.1097/01.sla.0000133083.54934.ae

C. Bassi, C. Dervenis, and G. Butturini, Postoperative pancreatic fistula: An international study group (ISGPF) definition, Surgery, vol.138, issue.1, pp.8-13, 2005.
DOI : 10.1016/j.surg.2005.05.001

H. Kim, J. Lee, and K. Paik, Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer, Surgery, vol.161, issue.6, pp.1579-87, 2017.
DOI : 10.1016/j.surg.2016.12.038

S. Jeon, J. Lee, and I. Joo, Magnetic resonance with diffusion-weighted imaging improves assessment of focal liver lesions in patients with potentially resectable pancreatic cancer on CT, European Radiology, vol.15, issue.8, pp.3484-93, 2018.
DOI : 10.1634/theoncologist.2010-0121

N. Van-der-gaag, E. Rauws, and C. Van-eijck, Preoperative Biliary Drainage for Cancer of the Head of the Pancreas, New England Journal of Medicine, vol.362, issue.2, pp.129-166, 2010.
DOI : 10.1056/NEJMoa0903230

J. Tol, J. Van-hooft, and R. Timmer, Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer, Gut, vol.13, issue.(2), pp.1981-1988, 2016.
DOI : 10.1007/s11894-010-0168-2

K. Slim, J. Blay, and A. Brouquet, Digestive oncology: surgical practices, J Chir, vol.146, issue.2, pp.11-80, 2009.

J. Mitchem, N. Hamilton, and F. Gao, Long-Term Results of Resection of Adenocarcinoma of the Body and Tail of the Pancreas Using Radical Antegrade Modular Pancreatosplenectomy Procedure, Journal of the American College of Surgeons, vol.214, issue.1, pp.46-52, 2012.
DOI : 10.1016/j.jamcollsurg.2011.10.008

C. Verbeke and K. Menon, Redefining resection margin status in pancreatic cancer, HPB, vol.11, issue.4, pp.282-291, 2009.
DOI : 10.1111/j.1477-2574.2009.00055.x
URL : https://doi.org/10.1111/j.1477-2574.2009.00055.x

J. Bryant and R. Day, Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials, Biometrics, vol.51, issue.4, pp.1372-83, 1995.
DOI : 10.2307/2533268

J. Klinkenbijl, J. Jeekel, and T. Sahmoud, Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary Region, Annals of Surgery, vol.230, issue.6, pp.230-776, 1999.
DOI : 10.1097/00000658-199912000-00006

F. Spitz, J. Abbruzzese, and J. Lee, Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas., Journal of Clinical Oncology, vol.15, issue.3, pp.928-965, 1997.
DOI : 10.1200/JCO.1997.15.3.928

M. Corsini, R. Miller, and M. Haddock, Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005), Journal of Clinical Oncology, vol.26, issue.21, pp.3511-3517, 2008.
DOI : 10.1200/JCO.2007.15.8782

J. Herman, M. Swartz, and C. Hsu, Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins Hospital, Journal of Clinical Oncology, vol.26, issue.21, pp.3503-3513, 2008.
DOI : 10.1200/JCO.2007.15.8469

S. Schorn, I. Demir, and C. Reyes, The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma ??? A systematic review and meta-analysis, Cancer Treatment Reviews, vol.55, pp.96-106, 2017.
DOI : 10.1016/j.ctrv.2017.03.003

M. Kanda, T. Fujii, and T. Sahin, Invasion of the Splenic Artery Is a Crucial Prognostic Factor in Carcinoma of the Body and Tail of the Pancreas, Annals of Surgery, vol.251, issue.3, pp.483-490, 2010.
DOI : 10.1097/SLA.0b013e3181cf9171

T. Schnelldorfer, A. Ware, and M. Sarr, Long-Term Survival After Pancreatoduodenectomy for Pancreatic Adenocarcinoma, Annals of Surgery, vol.247, issue.3, pp.456-62, 2008.
DOI : 10.1097/SLA.0b013e3181613142

M. Rajagopalan, D. Heron, and R. Wegner, Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer, Radiation Oncology, vol.8, issue.1, p.254, 2013.
DOI : 10.1016/j.anndiagpath.2011.08.005
URL : http://doi.org/10.1186/1748-717x-8-254

M. Katz, Q. Shi, and S. Ahmad, Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer, JAMA Surgery, vol.151, issue.8, p.161137, 2016.
DOI : 10.1001/jamasurg.2016.1137
URL : http://archsurg.jamanetwork.com/data/journals/surg/935586/soi160019.pdf

H. Burris, M. Moore, and J. Andersen, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial., Journal of Clinical Oncology, vol.15, issue.6, pp.2403-2416, 1997.
DOI : 10.1200/JCO.1997.15.6.2403

N. Maisey, I. Chau, and D. Cunningham, Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer, Journal of Clinical Oncology, vol.20, issue.14, pp.3130-3136, 2002.
DOI : 10.1200/JCO.2002.09.029

G. Colucci, F. Giuliani, and V. Gebbia, Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma, Cancer, vol.80, issue.4, pp.902-912, 2002.
DOI : 10.1002/cncr.10323

G. Colucci, R. Labianca, D. Costanzo, and F. , Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study, Journal of Clinical Oncology, vol.28, issue.10, pp.1645-51, 2010.
DOI : 10.1200/JCO.2009.25.4433

V. Heinemann, H. Wilke, and H. Mergenthaler, Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer, Annals of Oncology, vol.11, issue.11, pp.1399-403, 2000.
DOI : 10.1023/A:1026595525977

C. Louvet, R. Labianca, and P. Hammel, Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial, Journal of Clinical Oncology, vol.23, issue.15, pp.3509-3525, 2005.
DOI : 10.1200/JCO.2005.06.023

E. Poplin, Y. Feng, and J. Berlin, Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group, Journal of Clinical Oncology, vol.27, issue.23, pp.3778-85, 2009.
DOI : 10.1200/JCO.2008.20.9007

A. Wagner, P. Buechner-steudel, and A. Wein, Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO), Annals of Oncology, vol.18, issue.1, pp.82-89, 2007.
DOI : 10.1093/annonc/mdl340

A. Novarino, I. Chiappino, and G. Bertelli, Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer, Annals of Oncology, vol.15, issue.3, pp.474-481, 2004.
DOI : 10.1093/annonc/mdh106

V. Hess, S. Pratsch, and S. Potthast, Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial, Annals of Oncology, vol.3, issue.12, pp.2390-2395, 2010.
DOI : 10.1371/journal.pone.0004003

P. Correale, F. Montagnani, and S. Miano, Biweekly Triple Combination Chemotherapy with Gemcitabine, Oxaliplatin, Levofolinic Acid and 5-Fluorouracil (GOLF) Is a Safe and Active Treatment for Patients with Inoperable Pancreatic Cancer, Journal of Chemotherapy, vol.11, issue.1, pp.119-144, 2008.
DOI : 10.1111/j.1440-1746.2005.04022.x

T. Conroy, B. Paillot, and E. Francois, Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer???A Groupe Tumeurs Digestives of the F??d??ration Nationale des Centres de Lutte Contre le Cancer Study, Journal of Clinical Oncology, vol.23, issue.6, pp.1228-1264, 2005.
DOI : 10.1200/JCO.2005.06.050

T. Conroy, F. Desseigne, and M. Ychou, FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine, vol.364, issue.19, pp.1817-1842, 2011.
DOI : 10.1056/NEJMoa1011923
URL : https://hal.archives-ouvertes.fr/hal-00598658

K. Gunturu, X. Yao, and X. Cong, FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity, Medical Oncology, vol.5, issue.1, 2013.
DOI : 10.1159/000336156

L. Marthey, A. Sa-cunha, and J. Blanc, FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort, Annals of Surgical Oncology, vol.17, issue.11, pp.295-301, 2015.
DOI : 10.1245/s10434-010-1285-8

A. Goel, M. Grossbard, and S. Malamud, Pooled efficacy analysis from a phase I???II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer, Anti-Cancer Drugs, vol.18, issue.3, pp.263-71, 2007.
DOI : 10.1097/CAD.0b013e3280121334

M. Reni, N. Sartori, and A. Mambrini, An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?, Anti-Cancer Drugs, vol.21, issue.4, pp.459-64, 2010.
DOI : 10.1097/CAD.0b013e328336f50e

J. Farrell, H. Elsaleh, and M. Garcia, Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer, Gastroenterology, vol.136, issue.1, pp.187-95, 2009.
DOI : 10.1053/j.gastro.2008.09.067

R. Marechal, J. Bachet, and J. Mackey, Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma, Gastroenterology, vol.143, issue.3, pp.664-74, 2012.
DOI : 10.1053/j.gastro.2012.06.006

N. Bird, M. Elmasry, and R. Jones, Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy, British Journal of Surgery, vol.88, issue.Suppl 3
DOI : 10.1210/jc.2002-021353

, Br J Surg, vol.104, pp.328-364, 2017.

R. Yamada, S. Mizuno, and K. Uchida, Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy, Pancreas, vol.45, issue.5, pp.761-71, 2016.
DOI : 10.1097/MPA.0000000000000597

M. Lutz, J. Zalcberg, and M. Ducreux, 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer, European Journal of Cancer, vol.79, pp.41-50, 2017.
DOI : 10.1016/j.ejca.2017.03.022

P. Hosein, J. Macintyre, and C. Kawamura, A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma, BMC Cancer, vol.12, issue.Suppl 4, 0199.
DOI : 10.1016/S1470-2045(10)70237-0

J. Faris, L. Blaszkowsky, and S. Mcdermott, FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience, The Oncologist, vol.18, issue.5, pp.543-551, 2013.
DOI : 10.1634/theoncologist.2012-0435

M. Ducreux, E. Mitry, and M. Ould-kaci, Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients, Annals of Oncology, vol.15, issue.3, pp.467-73, 2004.
DOI : 10.1093/annonc/mdh098

M. Ghosn, F. Farhat, and J. Kattan, FOLFOX-6 Combination as the First-Line Treatment of Locally Advanced and/or Metastatic Pancreatic Cancer, American Journal of Clinical Oncology, vol.30, issue.1, pp.15-20, 2007.
DOI : 10.1097/01.coc.0000235997.18657.a6

V. Gebbia, E. Maiello, and F. Giuliani, Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice, Annals of Oncology, vol.18, issue.Supplement 6, pp.124-131, 2007.
DOI : 10.1093/annonc/mdm240

A. Novarino, M. Satolli, and I. Chiappino, Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer, American Journal of Clinical Oncology, vol.32, issue.1, pp.44-52, 2009.
DOI : 10.1097/COC.0b013e31817be5a9

U. Pelzer, I. Schwaner, and J. Stieler, Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group, European Journal of Cancer, vol.47, issue.11, pp.1676-81, 2011.
DOI : 10.1016/j.ejca.2011.04.011

C. Yoo, J. Hwang, and J. Kim, A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer, British Journal of Cancer, vol.69, issue.10, pp.1658-63, 2009.
DOI : 10.1002/cncr.23810
URL : http://www.nature.com/bjc/journal/v101/n10/pdf/6605374a.pdf

A. Zaanan, I. Trouilloud, and T. Markoutsaki, FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study, BMC Cancer, vol.73, issue.5???6, 2014.
DOI : 10.1159/000134477
URL : https://doi.org/10.1186/1471-2407-14-441